U.S. health officials question results from AstraZeneca’s vaccine trial, less than a day after they came out.

The New York Times | March 23, 2021, 4:54 a.m. | Original
Your Tuesday Briefing Study results strengthen the case for using Regeneron’s antibody cocktail in high-risk Covid patients.